Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2007 Jul;48(7):751-753. Korean.
    Published online Jul 31, 2007.
    https://doi.org/10.4111/kju.2007.48.7.751
    Copyright © 2007 The Korean Urological Association
    Case Report

    Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient

    Kyo Ik Mo, Ki Ho Kim, Young Jin Seo and Kyung Seop Lee
      • Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea.
    • Corresponding author (Email: ksleemd@dongguk.ac.kr )
    Received April 19, 2007; Accepted May 23, 2007.

    Abstract

    In some patients with prostate cancer and who manifest disease progression during maximal androgen blockade (MAB) therapy, discontinuation of antiandrogen treatment might result in a significant fall in the level of serum prostate-specific antigen (PSA), and this is often correlated with clinical improvement (antiandrogen withdrawal syndrome). However, a decline in the PSA level after the withdrawal of estramustine phosphate is extremely rare. We report here on a case of dramatic decline in the PSA level after withdrawal of estramustine phosphate in a patient with hormone refractory prostate cancer.

    Keywords
    Prostate cancer; Estramustine; Chemotherapy

    Figures

    Fig. 1
    Serial changes of bone scan finding. (A) Initial bone scan, (B) 38 months later (after second line hormone therapy), (C) 57 months later (after estramustine withdrawal).

    Fig. 2
    Clinical course. The serum prostate-specific antigen (PSA) level declined dramatically after the withdrawal of estramustine phosphate. PSA: prostate-specific antigen, MAB: maximal androgen blockade, GnRH: gonadotrophin releasing hormone, K: ketoconazole, P: prednisolone, E: estramustine, V: vinblastine.

    References

      1. Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993;149:607–609.
      1. Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 1998;5:44–47.
      1. Shibata Y, Morita T, Kashiwagi B, Tomizawa H, Yamanaka H. Estramustine phosphate withdrawal syndrome with dramatic pain relief. J Urol 1999;162:805.
      1. Kobayashi M, Kuramoto H, Ota J, Fujimoto N. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer. Int J Urol 2006;13:1019–1021.
      1. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004;91:3–12.
      1. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153–158.
      1. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nucleic Acids Res 1998;26:234–238.
      1. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999;17:3160–3166.
    MeSH Terms
    Disease Progression
    Drug Therapy
    Estramustine*
    Humans
    Prostate*
    Prostatic Neoplasms*
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    PERMALINK